C9orf72 and amyotrophic lateral sclerosis: Furthermore, consistent with the DAB IHC (Fig. 2A), co-immunolabelling of PML antibody together with either the pTDP-43 antibody in C9orf72 (Fig. 2B, C) or with FUS antibody in FUS-ALS-FTD cases (Fig. 2D) revealed an overall profound reduction of PML-NB number in the α-MNs compared to the controls.